Development of small-molecule inhibitors against hantaviruses

Deng, Xiaoqian; Tian, Shijun; Yu, Zhengsen; Wang, Lili; Liang, Ruiying; Li, Yanbai; Xiang, Rong; Jiang, Shibo; Ying, Tianlei; Yu, Fei

doi:10.1016/j.micinf.2020.05.011

Cited by 2 publications

(1 citation statement)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Small molecules also gained importance for their antiviral potential ( Deng et al, 2020 ). Baloxavir, a recently licensed influenza medication derived from BXM, is an endonuclease-targeting small molecule that prevents the translation of the influenza virus and also prevents the virus from replicating.…”

Section: Recent Therapeutic Advances Against Hantavirusmentioning

confidence: 99%

Hantavirus: an overview and advancements in therapeutic approaches for infection

Afzal,

Ali,

Batool

et al. 2023

Front. Microbiol.

View full text Add to dashboard Cite

Hantaviruses are a significant and emerging global public health threat, impacting more than 200,000 individuals worldwide each year. The single-stranded RNA viruses belong to the Hantaviridae family and are responsible for causing two acute febrile diseases in humans: Hantavirus pulmonary syndrome (HPS) and hemorrhagic fever with renal syndrome (HFRS). Currently, there are no licensed treatments or vaccines available globally for HTNV infection. Various candidate drugs have shown efficacy in increasing survival rates during the early stages of HTNV infection. Some of these drugs include lactoferrin, ribavirin, ETAR, favipiravir and vandetanib. Immunotherapy utilizing neutralizing antibodies (NAbs) generated from Hantavirus convalescent patients show efficacy against HTNV. Monoclonal antibodies such as MIB22 and JL16 have demonstrated effectiveness in protecting against HTNV infection. The development of vaccines and antivirals, used independently and/or in combination, is critical for elucidating hantaviral infections and the impact on public health. RNA interference (RNAi) arised as an emerging antiviral therapy, is a highly specific degrades RNA, with post-transcriptional mechanism using eukaryotic cells platform. That has demonstrated efficacy against a wide range of viruses, both in vitro and in vivo. Recent antiviral methods involve using small interfering RNA (siRNA) and other, immune-based therapies to target specific gene segments (S, M, or L) of the Hantavirus. This therapeutic approach enhances viral RNA clearance through the RNA interference process in Vero E6 cells or human lung microvascular endothelial cells. However, the use of siRNAs faces challenges due to their low biological stability and limited in vivo targeting ability. Despite their successful inhibition of Hantavirus replication in host cells, their antiviral efficacy may be hindered. In the current review, we focus on advances in therapeutic strategies, as antiviral medications, immune-based therapies and vaccine candidates aimed at enhancing the body’s ability to control the progression of Hantavirus infections, with the potential to reduce the risk of severe disease.

show abstract

Section: Recent Therapeutic Advances Against Hantavirusmentioning

confidence: 99%

Hantavirus: an overview and advancements in therapeutic approaches for infection

Afzal,

Ali,

Batool

et al. 2023

Front. Microbiol.

View full text Add to dashboard Cite

show abstract

Small molecules against viruses causing hemorrhagic fevers in Russia

Laev,

Yarovaya,

Salakhutdinov

2024

RUSS CHEM REV

View full text Add to dashboard Cite

This review is devoted to small molecules (compounds with molecular weights of up to 800–900 Da) that show activity against viruses causing hemorrhagic fevers. Despite the wide occurrence of hemorrhagic fevers, effective medications for their prevention and treatment are virtually absent. Currently, the search for a new drug to fight these viruses is still a relevant task, since the synthetic nucleoside ribavirin used in clinical practice is not sufficiently effective. The review presents compounds that have antiviral action against the causative agents or alleviate symptoms of three acute infectious diseases occurring in Russia: Omsk hemorrhagic fever, Crimean-Congo hemorrhagic fever, and hemorrhagic fever with renal syndrome. The structures and activity parameters (half maximal inhibitory concentration) of the compounds are given and hypothesized mechanisms of their action are considered. The data published during the whole period of studies of these diseases are summarized. <br>The bibliography includes 160 references.

show abstract

Development of small-molecule inhibitors against hantaviruses

Cited by 2 publications

References 54 publications

Hantavirus: an overview and advancements in therapeutic approaches for infection

Hantavirus: an overview and advancements in therapeutic approaches for infection

Small molecules against viruses causing hemorrhagic fevers in Russia

Contact Info

Product

Resources

About